Immunologic Changes after Rush Allergen-Specific Immunotherapy in Children

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20170825001

Enrollment

Registered

2017-08-25

Start date

2017-02-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children with allergic diseases: AR&#44

Interventions

children received rush allergen&#45

specific immunotherapy

Basic Science

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: children with AR, AD, Asthma, or insect bite anaphylaxis

Exclusion criteria

Exclusion criteria: uncontrolled asthma receiving or just stop other immunotherapy in the past 5 years underlying diseases: cardiovascular diseases, malignancy have current medications: beta-blocker, ACEI

Design outcomes

Primary

Measure	Time frame
changing of regulatory T cells before start immunotherapy, after rush schedules, after reaching maintenance dose, and 6-month later percentage of CD4+CD25+FOXP3+ T cells in total CD4+ T cells	—

Secondary

Measure	Time frame
clinical of allergic rhinitis before start immunotherapy, after reaching maintenance dose, and 6-month later allergic rhinitis symptom-free day,clinical of atopic dermatitis before start immunotherapy, after reaching maintenance dose, and 6-month later SCORAD scales	—

Countries

Thailand

Contacts

Public ContactTipyapa Rattanamanee

Faculty of Medicine Ramathibodi Hospital, Mahidol University

tipyapa.rl@gmail.com081-4061342

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Immunologic Changes after Rush Allergen&#45;Specific Immunotherapy in Children